Standard BioTools Inc. (LAB)
1.15
-0.06 (-4.96%)
At close: Mar 24, 2025, 3:59 PM
1.16
0.89%
After-hours: Mar 24, 2025, 07:56 PM EDT
-4.96% (1D)
| Bid | 1.14 |
| Market Cap | 433.94M |
| Revenue (ttm) | 187.14M |
| Net Income (ttm) | -149.01M |
| EPS (ttm) | -0.52 |
| PE Ratio (ttm) | -2.2 |
| Forward PE | -10.65 |
| Analyst | Buy |
| Ask | 1.17 |
| Volume | 866,557 |
| Avg. Volume (20D) | 1,958,558 |
| Open | 1.23 |
| Previous Close | 1.21 |
| Day's Range | 1.14 - 1.26 |
| 52-Week Range | 0.99 - 3.04 |
| Beta | 1.62 |
About LAB
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immu...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Feb 10, 2011
Employees 814
Stock Exchange NASDAQ
Ticker Symbol LAB
Website https://www.fluidigm.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LAB stock is "Buy." The 12-month stock price forecast is $2.88, which is an increase of 151.53% from the latest price.
Stock ForecastsNext Earnings Release
Standard BioTools Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+26.38%
Standard BioTools shares are trading higher after ...
Unlock content with
Pro Subscription
7 months ago
-36.61%
Standard BioTools shares are trading lower after the company reported worse-than-expected Q2 financial results and cut FY24 revenue guidance below estimates. The company announced CFO Jeffery Black will resign.
